Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» More Positive Results For Takeda's Alunbrig Acquisition
More Positive Results For Takeda's Alunbrig Acquisition
More Positive Results For Takeda's Alunbrig Acquisition
Submitted by
admin
on July 25, 2018 - 9:34am
Source:
CP Wire
News Tags:
Takeda
Alunbrig
ALK-positive non-small cell lung cancer
Headline:
More Positive Results For Takeda's Alunbrig Acquisition
snippet:
Alunbrig demonstrated statistically superior progression-free survival vs crizotinib in patients with ALK+ NSCLC
Alunbrig previously received accelerated approval from the FDA for ALK+ advanced NSCLC
The drug was also awarded Breakthrough Therapy Designation and Orphan Drug Status by the FDA
Do Not Allow Advertisers to Use My Personal information
